US › Healthcare

Tempest Therapeutics Inc (TPST)

US · Healthcare · Biotechnology

$0.62-1.73%

Last close · 2026-10-16

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-5.2M

EPS

$-0.34

EPS estimate

$-0.30

EPS came in at -0.34 against a street estimate of -0.30 — a miss of 13.3%.

Key statistics

Market cap

$10.5M

Forward P/E

0.0

P/B

22.94

Book value

$-0.07

EPS (TTM)

$-3.93

52-week high

$11.13

52-week low

$0.62

50-day MA

$0.93

200-day MA

$1.62

Beta

-1.71

Analyst view

Analysts rate Tempest Therapeutics Inc a strong buy (1 buy, 0 hold, 0 sell out of 1) with an average price target of $7.00.

Shareholding

Insiders

30.07%

Institutions

27.98%

Largest institutional holders

Fund	Stake
Sabby Management LLC	3.03%
Vanguard Capital Management, LLC	1.38%
Geode Capital Management, LLC	0.51%
Vanguard Fiduciary Trust Co	0.41%
BlackRock Inc	0.23%
Squarepoint Ops LLC	0.18%
Northern Trust Corp	0.12%
Citadel Advisors Llc	0.12%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Tempest Therapeutics Inc — free to start.

Open in the app Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc UnitedHealth Group Incorporated Merck & Company Inc Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Gilead Sciences Inc Abbott Laboratories Novo Nordisk A/S

Data updated 2026-10-19.